Registry of Lobbyists
Active
-
Last Updated:
2024-04-26
| Subject matters | Details | Categories |
|---|---|---|
|
Budget,
Health,
Industry
|
Bill C-64: An Act respecting pharmacare, with a particular focus on access to medicines and rare disease and orphan drug policies
|
Legislative Proposal, Bill or Resolution
|
|
Budget,
Health,
Industry
|
Engagement with officials on issues related to the National Strategy for Rare Disease Drugs, and other policies or programs related to rare diseases.
|
Policies or Program
|
|
Budget,
Health,
Industry
|
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with the Canadian Agency for Drugs and Technologies in Health (CADTH), Canada's Drug Agency and/or other pan-Canadian health organizations.
|
Policies or Program
|
|
Budget,
Health,
Industry
|
Federally-funded public drug plans, with respect to reimbursement fof medicines for federal plan beneficiaries.
|
Policies or Program
|
|
Budget,
Health,
Industry
|
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
|
Policies or Program,
Regulation
|
|
Budget,
Health,
Industry,
Research and Development,
Science and Technology
|
Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda, the Biomanufacturing and Life Sciences Strategu and other government policies and programs related to incentivizing research and development activities in Canada.
|
Policies or Program
|
|
Health
|
Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases.
|
Policies or Program,
Regulation
|
| Subject matters | Details | Categories |
|---|---|---|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federal programs and budgetary initiatives related to the Federal-Provincial-Territorial funding arrangements regarding pharmaceuticals including addressing any health technology assessment-related or other policy discussions that might involve Health Canada and its ongoing relationship with the Canadian Agency for Drugs and Technologies in Health (CADTH) and/or other pan-Canadian health organizations.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Federally-funded public drug plans, with respect to reimbursement for drug products for federal plan beneficiaries.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Guidelines, policies and programs related to regulatory and reporting functions of the Patented Medicine Prices Review Board
|
Policies or Program,
Regulation
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Innovation, Science and Economic Development Canada regarding the Innovation and Skills Agenda and other government policies and programs related to incentivizing research and development activities in Canada.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Proposals to amend guidelines related to the operationalization of the legislation and regulations governing the Patented Medicine Prices Review Board
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Provincial programs and policies regarding rare disorders and orphan drugs.
|
Policies or Program
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
Regulatory amendments and/or guidelines and/or policies related to the Food and Drugs Act and Health Canada review of drugs for rare diseases.
|
Policies or Program,
Regulation
|
|
Subject matters were not required to be associated with subject matter details when this content was submitted
|
The federal role in considering developing and/or funding a national pharmacare program, including engagement with the Advisory Council on the Implementation of National Pharmacare and its Secretariat on issues related to access to medicines and rare disease and orphan drug policies
|
Policies or Program
|
Communication techniques that have been used or are expected to be used in the course of the undertaking: